<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bendamustine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bendamustine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Bendamustine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11984" href="/d/html/11984.html" rel="external">see "Bendamustine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F5957167"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Belrapzo;</li>
<li>Bendeka;</li>
<li>Treanda;</li>
<li>Vivimusta</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868945"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Benvyon;</li>
<li>NAT-Bendamustine;</li>
<li>Treanda</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F5957171"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Alkylating Agent;</li>
<li>
                        Antineoplastic Agent, Alkylating Agent (Nitrogen Mustard)</li></ul></div>
<div class="block doa drugH1Div" id="F5958743"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Bendamustine is associated with a moderate emetic potential (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>); antiemetics are recommended to prevent nausea and vomiting. Infection prophylaxis and/or treatment may be required prior to bendamustine administration. Vigorous hydration and tumor lysis syndrome prophylactic measures (eg, antihyperuricemic therapy) should be instituted prior to bendamustine treatment in high-risk patients. ANC should recover to ≥1,000/mm<sup>3</sup> and platelets to ≥75,000/mm<sup>3</sup> prior to cycle initiation.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1c2daff1-da41-460d-97f5-616d486189ba">Chronic lymphocytic leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic lymphocytic leukemia:</b>
<b>IV:</b> 100 mg/m<sup>2</sup> on days 1 and 2 of a 28-day treatment cycle (as a single agent) for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19652068','lexi-content-ref-22861163']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19652068','lexi-content-ref-22861163'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Chronic lymphocytic leukemia, first-line treatment (off-label dosing):</b>
<b>IV:</b> 90 mg/m<sup>2</sup> on days 1 and 2 of a 28-day treatment cycle (in combination with rituximab) for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22869884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22869884'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Chronic lymphocytic leukemia, relapsed/refractory (off-label dosing):</b>
<b>IV:</b> 70 mg/m<sup>2</sup> on days 1 and 2 of a 28-day treatment cycle (in combination with rituximab) for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21844497']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21844497'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6d4c856e-dedc-4b57-9bc3-4eb783e31618">Non-Hodgkin lymphomas</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-Hodgkin lymphomas:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Lymphoma, diffuse large B-cell (DLBC), relapsed or refractory (off-label dosing/combination):</i>
<b>IV:</b> 90 mg/m<sup>2</sup> on days 2 and 3 of a 21-day treatment cycle (cycle 1), and then 90 mg/m<sup>2</sup> on days 1 and 2 of a 21-day treatment cycle for 5 cycles (cycles 2 through 6) (in combination with polatuzumab vedotin and rituximab) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31693429']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31693429'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Lymphoma, indolent B-cell, refractory:</i>
<b> IV:</b> 120 mg/m<sup>2</sup> on days 1 and 2 of a 21-day treatment cycle (as a single agent) for up to 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19890959']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19890959'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Lymphoma, indolent (eg, follicular, marginal zone) and mantle cell; first-line treatment (off-label use):</i>
<b>IV:</b> 90 mg/m<sup>2</sup> over 30 to 60 minutes on days 1 and 2 of a 28-day treatment cycle (in combination with rituximab) for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23433739']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23433739'])">Ref</a></span>) <b>or</b> 90 mg/m<sup>2</sup> over 30 minutes on days 1 and 2 of a 28-day treatment cycle (in combination with rituximab) for 6 to 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24591201']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24591201'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Lymphoma, follicular, relapsed or refractory (off-label dosing):</i>
<b>IV:</b> 90 mg/m<sup>2</sup> over 60 minutes on days 1 and 2 of a 35-day treatment cycle (in combination with bortezomib and rituximab) for 5 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21810687']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21810687'])">Ref</a></span>) <b>or</b> 90 mg/m<sup>2</sup> on days 1 and 2 of a 28-day treatment cycle for 6 cycles (in combination with obinutuzumab, then followed by obinutuzumab monotherapy in patients with stable disease, complete response, or partial response after 6 cycles of combination therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27345636']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27345636'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Lymphoma, mantle cell, relapsed or refractory (off-label use):</i>
<b>IV:</b> 90 mg/m<sup>2</sup> over 30 minutes on days 2 and 3 of a 28-day treatment cycle (in combination with rituximab) for up to 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15908650']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15908650'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4ebbaa33-8ab0-44b8-a662-fd68c7d18267">Hodgkin lymphoma, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma, relapsed or refractory (off-label use):</b>
<b>IV:</b> 120 mg/m<sup>2</sup> over 30 minutes on days 1 and 2 of a 28-day treatment cycle for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23248254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23248254'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9de36ebf-bf40-40d1-a8d9-de7326490045">Multiple myeloma, salvage therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma, salvage therapy (off-label use):</b>
<b>IV:</b> 90 to 100 mg/m<sup>2</sup> on days 1 and 2 of a 28-day treatment cycle for at least 2 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16154860']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16154860'])">Ref</a></span>) <b>or</b> 75 mg/m<sup>2</sup> on days 1 and 2 of a 28-day treatment cycle (in combination with lenalidomide and dexamethasone) for up to 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22451423']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22451423'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a7e51133-3365-497f-a5f7-67ab5a320365">Waldenström macroglobulinemia, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Waldenström macroglobulinemia, refractory (off-label use): IV:</b> 90 mg/m<sup>2</sup> on days 1 and 2 of a 28-day treatment cycle (in combination with rituximab) for 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21454214']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21454214'])">Ref</a></span>) <b>or</b> 90 mg/m<sup>2</sup> over 30 minutes on days 2 and 3 of a 28-day treatment cycle (in combination with rituximab) for 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15908650']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15908650'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990342"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Kenar D. Jhaveri, MD, Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: </b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute: <b>IV:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25829094','lexi-content-ref-20140617','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25829094','lexi-content-ref-20140617','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute: <b>IV:</b> No dosage adjustment necessary (minimal excretion of active parent drug by the kidney) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sandhu.1','lexi-content-ref-30942181','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sandhu.1','lexi-content-ref-30942181','lexi-content-ref-Expert.DOR'])">Ref</a></span>). Although use is not recommended according to prescribing information, studies suggest bendamustine may be used in this patient population (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26085055','lexi-content-ref-28664772','lexi-content-ref-22526157','lexi-content-ref-24046251','lexi-content-ref-29168251']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26085055','lexi-content-ref-28664772','lexi-content-ref-22526157','lexi-content-ref-24046251','lexi-content-ref-29168251'])">Ref</a></span>). Incidence of grade 3/4 adverse effects may be higher, including thrombocytopenia and increased BUN. Close monitoring of blood counts and kidney function is needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23987821']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23987821'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be significantly removed by dialysis (highly protein bound): <b>IV:</b> No dosage adjustment necessary. Patients may have higher risk of leukopenia and thrombocytopenia; monitor blood counts closely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29385883','lexi-content-ref-33938097','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29385883','lexi-content-ref-33938097','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly removed by dialysis (highly protein bound): <b>IV:</b> No dosage adjustment necessary; patients may have higher risk of leukopenia and thrombocytopenia; monitor blood counts closely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23645657','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23645657','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: IV: </b>No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): IV: </b>No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987704"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment: A pharmacokinetic study showed only slight differences in bendamustine AUC and C<sub>max</sub> in patients with mild hepatic impairment (defined in the study as total bilirubin 1 to 1.5 times ULN or AST greater than ULN), compared to patients with normal hepatic function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20140617']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20140617'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate impairment (AST or ALT 2.5 to 10 times ULN and total bilirubin 1.5 to 3 times ULN): Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (total bilirubin &gt;3 times ULN): Use is not recommended.</p></div>
<div class="block doo drugH1Div" id="F20339757"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">
<i>American Society of Clinical Oncology </i>
<i>guidelines</i>
<i> for appropriate systemic therapy dosing in adults with cancer </i>
<i>with a BMI ≥30 kg/m<sup>2</sup></i>
<i>:</i> Utilize patient's actual body weight (full weight) for calculation of BSA- or weight-based dosing; manage regimen-related toxicities in the same manner as for patients with a BMI &lt;30 kg/m<sup>2</sup>; if a dose reduction is utilized due to toxicity, may consider resumption of full weight-based dosing (or previously tolerated dose level) with subsequent cycles only if dose escalations are allowed in the prescribing information, if contributing underlying factors (eg, hepatic or kidney impairment) are sufficiently resolved, AND if performance status has markedly improved or is considered adequate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33939491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33939491'])">Ref</a></span>).</p></div>
<div class="block dot drugH1Div" id="F5957403"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hypersensitivity (severe allergic reaction):</i> Discontinue bendamustine. Do not rechallenge for ≥ grade 3 allergic reaction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Infusion reactions:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Grade 1 or 2: Consider premedication with antihistamines, antipyretics, and corticosteroids in subsequent cycles.</p>
<p style="text-indent:-2em;margin-left:4em;">Grade 3: Consider discontinuing treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Grade 4: Discontinue treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Progressive multifocal leukoencephalopathy:</i> Withhold bendamustine and perform appropriate diagnostic evaluations for suspected progressive multifocal leukoencephalopathy (PML). Consider discontinuation or reduction of concomitant chemotherapy or immunosuppressive therapy in patients who develop PML.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Skin reaction, severe or progressive:</i> Withhold or discontinue bendamustine treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Treatment delay:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic toxicity ≥ grade 4: Delay treatment until resolves (ANC ≥1,000/mm<sup>3</sup>, platelets ≥75,000/mm<sup>3</sup>); reinitiate bendamustine with discretion (consider dose reduction).</p>
<p style="text-indent:-2em;margin-left:4em;">Nonhematologic toxicity ≥ grade 2 (clinically significant): Delay treatment until resolves to ≤ grade 1; reinitiate bendamustine with discretion (consider dose reduction).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Dose modification in CLL:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic toxicity ≥ grade 3: Reduce dose to 50 mg/m<sup>2</sup> on days 1 and 2 of each treatment cycle. For recurrent hematologic toxicity (≥ grade 3), further reduce dose to 25 mg/m<sup>2</sup> on days 1 and 2 of the treatment cycle. Consider re-escalating dose in subsequent cycles with discretion.</p>
<p style="text-indent:-2em;margin-left:4em;">Nonhematologic toxicity ≥ grade 3 (clinically significant): Reduce dose to 50 mg/m<sup>2</sup> on days 1 and 2 of the treatment cycle. Consider re-escalating dose in subsequent cycles with discretion.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Dose modification in NHL:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic toxicity grade 4: Reduce dose to 90 mg/m<sup>2</sup> on days 1 and 2 of each treatment cycle. For recurrent hematologic toxicity (grade 4), further reduce dose to 60 mg/m<sup>2</sup> on days 1 and 2 of each treatment cycle.</p>
<p style="text-indent:-2em;margin-left:4em;">Nonhematologic toxicity ≥ grade 3: Reduce dose to 90 mg/m<sup>2</sup> on days 1 and 2 of the treatment cycle with discretion. For recurrent toxicity ≥ grade 3, further reduce dose to 60 mg/m<sup>2</sup> on days 1 and 2 of each treatment cycle.</p></div>
<div class="block doe drugH1Div" id="F5957380"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F5957205"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (8% to 16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration (14%), weight loss (7% to 18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (13%), anorexia (23%), constipation (29%), decreased appetite (13%), diarrhea (9% to 37%; grades 3/4: 1% to 3%), dyspepsia (11%), nausea (20% to 75%; grades 3/4: ≤4%), stomatitis (15%; grades 3/4: &lt;1%), vomiting (16% to 40%; grades 3/4: ≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bone marrow depression (grades 3/4: 98%), decreased hemoglobin (88% to 89%; grades 3/4: 11% to 13%), decreased neutrophils (75% to 86%; grades 3/4: 43% to 60%), decreased platelet count (77% to 86%; grades 3/4: 11% to 25%), leukopenia (61% to 94%; grades 3/4: 28% to 56%), lymphocytopenia (68% to 99%; grades 3/4: 47% to 94%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum bilirubin (34%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (8% to 11%), chills (6% to 14%), dizziness (14%), fatigue (9% to 57%), headache (21%), insomnia (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (4% to 22%), dyspnea (16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (24% to 34%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (6%), exacerbation of hypertension (3%; including hypertensive crisis), hypotension (6%), tachycardia (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Hyperhidrosis (5%), night sweats (5%), pruritus (5% to 6%), xeroderma (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia (grades 3/4: 3%), hyperuricemia (7%), hypocalcemia (grades 3/4: 2%), hypokalemia (9%), hyponatremia (grades 3/4: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention (5%), dysgeusia (7%), gastroesophageal reflux disease (10%), oral candidiasis (6%), upper abdominal pain (5%), xerostomia (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Febrile neutropenia (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (grades 3/4: 3%), increased serum aspartate transaminase (grades 3/4: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes simplex infection (3%), herpes zoster infection (10%), infection (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Infusion-site pain (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (8%), depression (6%), pain (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (6%), limb pain (5%), ostealgia (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (grades 3/4: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasal congestion (5%), nasopharyngitis (6% to 7%), pharyngolaryngeal pain (8%), pneumonia (8%; including atypical pneumonia), sinusitis (9%), upper respiratory tract infection (10%), wheezing (5%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Bullous rash, dermatitis, erythema of skin, skin necrosis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Oral inflammation</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemolysis, tumor lysis syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Infusion-related reaction, nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Sepsis, septic shock</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drowsiness, malaise</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pulmonary fibrosis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarking:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, atrial fibrillation, heart failure, palpitations</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin carcinoma (non-melanoma; including basal cell carcinoma of skin and squamous cell carcinoma of skin), Stevens-Johnson syndrome, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Nephrogenic diabetes insipidus</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Acute myelocytic leukemia, myelodysplastic syndrome, pancytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatotoxicity</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Drug reaction with eosinophilia and systemic symptoms</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Infusion-site reaction (including infusion-site irritation, local pruritus, local swelling, localized phlebitis), injection-site reaction (including injection-site phlebitis, injection-site pruritus, irritation at injection site, pain at injection site, swelling at injection site)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Progressive multifocal leukoencephalopathy</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchogenic carcinoma, pneumonia due to <i>Pneumocystis jirovecii</i>, pneumonitis</p></div>
<div class="block coi drugH1Div" id="F5957180"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Known hypersensitivity (eg, anaphylactic or anaphylactoid reactions) to bendamustine or any component of the formulation. Belrapzo and Bendeka are also contraindicated in patients with hypersensitivity to polyethylene glycol 400, propylene glycol, or monothioglycerol. Vivimusta is also contraindicated in patients with hypersensitivity to polyethylene glycol 400, dehydrated alcohol, or monothioglycerol.</p></div>
<div class="block war drugH1Div" id="F5957181"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Myelosuppression (neutropenia, thrombocytopenia, and anemia) is a common toxicity; nadirs typically occurred in the third week of treatment. Complications due to febrile neutropenia and severe thrombocytopenia have been reported (some fatal).</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic toxicity: Serious and fatal dermatologic toxicities, including Stevens-Johnson syndrome and toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, bullous exanthema, and rash have been reported. Skin reactions have been reported with monotherapy and in combination with other antineoplastic agents or allopurinol and may be progressive or worsen with continued treatment. The risk for severe skin toxicity is increased with concurrent use of allopurinol and other medications known to cause skin toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Bendamustine is an irritant with vesicant-like properties; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. Erythema, marked swelling, and pain have been reported with extravasation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Serious and fatal cases of liver injury have been reported, usually within the first 3 months of treatment initiation. Confounding factors in some patients included combination therapy, progressive disease, and/or hepatitis B reactivation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity/infusion reaction: Infusion reactions, which may include chills, fever, pruritus, and rash, are common. Rarely, anaphylactic and anaphylactoid reactions have occurred, particularly with the second or subsequent cycle(s).</p>
<p style="text-indent:-2em;margin-left:4em;">• Infection: Pneumonia, hepatitis, sepsis, and septic shock have been reported. Fatalities due to infection have occurred. Patients with myelosuppression are more susceptible to infection. Reactivation of hepatitis B, cytomegalovirus, <i>Mycobacterium tuberculosis</i>, and herpes zoster infection may occur in patients receiving bendamustine.</p>
<p style="text-indent:-2em;margin-left:4em;">• Progressive multifocal leukoencephalopathy: Progressive multifocal leukoencephalopathy (PML), which may be fatal, has been reported, primarily when bendamustine was used in combination with obinutuzumab or rituximab. Consider PML with new-onset or changes in preexisting behavioral, cognitive, or neurological signs or symptoms.</p>
<p style="text-indent:-2em;margin-left:4em;">• Secondary malignancy: Malignancies (including myelodysplastic syndrome, myeloproliferative disorders, acute myeloid leukemia, bronchial cancer, and nonmelanoma skin cancer [basal and squamous cell cancer]) and premalignant diseases have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tumor lysis syndrome: Tumor lysis syndrome (usually occurring in the first treatment cycle) may occur as a consequence of antineoplastic treatment, including treatment with bendamustine. May lead to life-threatening acute renal failure (without intervention).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Formulations: Bendamustine is available as a liquid solution formulation (100 mg/4 mL [Belrapzo, Bendeka, Vivimusta]) and a powder for reconstitution (5 mg/mL after reconstitution [Treanda]). Concentrations, storage, and compatibility differ between formulations. Use caution when selecting bendamustine formulation for preparation and administration. Do not mix or combine the formulations.</p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007). See manufacturer's labeling.</p></div>
<div class="block foc drugH1Div" id="F5957484"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Belrapzo: 100 mg/4 mL (4 mL) [contains polyethylene glycol (macrogol), propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bendeka: 100 mg/4 mL (4 mL) [contains polyethylene glycol (macrogol), propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vivimusta: 100 mg/4 mL (4 mL) [contains alcohol, usp, polyethylene glycol (macrogol)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/4 mL (4 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg (1 ea); 100 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Treanda: 25 mg (1 ea); 100 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg (1 ea); 100 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F5957169"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16321818"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Belrapzo Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/4 mL (per mL): $780.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Bendamustine HCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/4 mL (per mL): $702.00 - $962.86</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Bendeka Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/4 mL (per mL): $742.14</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Bendamustine HCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $156.00 - $480.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $660.00 - $1,920.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Treanda Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $891.54</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $3,566.16</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868946"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Benvyon: 25 mg/mL (1 mL, 4 mL, 8 mL) [contains alcohol, usp, polyethylene glycol (macrogol)]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Treanda: 25 mg (1 ea); 100 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg (1 ea); 100 mg (1 ea)</p></div>
<div class="block adm drugH1Div" id="F5957404"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> For chronic lymphocytic leukemia, infuse over 30 minutes (Belrapzo, Treanda), 20 minutes (Vivimusta), or 10 minutes (Bendeka). For non-Hodgkin lymphoma, infuse over 60 minutes (Belrapzo, Treanda), 20 minutes (Vivimusta), or 10 minutes (Bendeka). Administration times for off-label uses/doses vary by protocol.</p>
<p style="text-indent:-2em;margin-left:2em;">Consider premedication with antihistamines, antipyretics, and corticosteroids for patients with a previous grade 1 or 2 infusion reaction to bendamustine. Bendamustine is associated with a moderate emetic potential (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>); antiemetics are recommended to prevent nausea and vomiting.</p>
<p style="text-indent:-2em;margin-left:2em;">Irritant with vesicant-like properties; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation; monitor IV site for redness, swelling, or pain.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Apply dry cold compresses for 20 minutes 4 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22997449']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22997449'])">Ref</a></span>). May be managed with sodium thiosulfate in the same manner as mechlorethamine extravasation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21255716']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21255716'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Sodium thiosulfate 1/6 M solution (instructions for mechlorethamine):</i> Inject subcutaneously into extravasation area using 2 mL for each mg of drug suspected to have extravasated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22997449','lexi-content-ref-Polovich.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22997449','lexi-content-ref-Polovich.1'])">Ref</a></span>).</p></div>
<div class="block hazard drugH1Div" id="F49130899"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F5957173"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic lymphocytic leukemia:</b> Treatment of chronic lymphocytic leukemia (CLL).</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Efficacy relative to first-line therapies for CLL other than chlorambucil has not been established.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-Hodgkin lymphoma, indolent (refractory):</b> Treatment of indolent B-cell non-Hodgkin lymphoma (NHL) which has progressed during or within 6 months of rituximab treatment or a rituximab-containing regimen.</p></div>
<div class="block off-label drugH1Div" id="F25475187"><span class="drugH1">Use: Off-Label: Adult</span><p>Hodgkin lymphoma (relapsed or refractory); Multiple myeloma (salvage therapy); Non-Hodgkin lymphoma, diffuse large B-cell (relapsed or refractory); Non-Hodgkin lymphoma, indolent (eg, follicular, marginal zone), and mantle cell; first-line treatment; Non-Hodgkin lymphoma, mantle cell (relapsed or refractory); Waldenström macroglobulinemia</p></div>
<div class="block mst drugH1Div" id="F5957165"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Bendamustine may be confused with brentuximab, carmustine, lomustine.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Different formulation issues: Bendamustine is available as a liquid solution formulation (100 mg/4 mL [Belrapzo, Bendeka]) and a powder for reconstitution (5 mg/mL after reconstitution [Treanda]). Concentrations, storage, and compatibility differ between formulations. Use caution when selecting bendamustine formulation for preparation and administration (ISMP [Smetzer 2015]). Do not mix or combine the formulations.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F5957266"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of BCRP/ABCG2, CYP1A2 (minor), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F5957265"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Allopurinol: May enhance the adverse/toxic effect of Bendamustine. Specifically, the risk of severe skin reactions may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inducers (Moderate): May decrease the serum concentration of Bendamustine. Concentrations of active metabolites may be increased. Management: Consider alternatives to moderate CYP1A2 inducers during therapy with bendamustine due to the potential for decreased bendamustine plasma concentrations and reduced efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inhibitors (Moderate): May increase the serum concentration of Bendamustine. Management: Consider alternatives to moderate CYP1A2 inhibitors during therapy with bendamustine due to the potential for increased bendamustine plasma concentrations and increased bendamustine toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inhibitors (Strong): May increase the serum concentration of Bendamustine. Concentrations of the active metabolites of bendamustine may be decreased. Management: Consider alternatives to strong CYP1A2 inhibitors during therapy with bendamustine due to the potential for increased bendamustine plasma concentrations and increased bendamustine toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49095580"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use in patients who can become pregnant. Patients who can become pregnant should use effective contraception during therapy and for 6 months after the last bendamustine dose. Patients with partners who can become pregnant should use effective contraception during therapy and for 3 months after the last dose of bendamustine.</p>
<p style="text-indent:0em;margin-top:2em;">Adverse effects to male fertility have been observed in clinical studies. Effects include impaired spermatogenesis, azoospermia, and total germinal aplasia. Risks are increased with combination therapy. Spermatogenesis may return in some patients following remission and may occur several years after therapy has been discontinued.</p></div>
<div class="block pri drugH1Div" id="F5957176"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and data from animal reproduction studies, in utero exposure to bendamustine may cause fetal harm.</p>
<p style="text-indent:0em;margin-top:2em;">The European Society for Medical Oncology has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy; the guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team). In general, if chemotherapy is indicated, it should be avoided in the first trimester and there should be a 3-week time period between the last chemotherapy dose and anticipated delivery, and chemotherapy should not be administered beyond week 33 of gestation (ESMO [Peccatori 2013]).</p>
<p style="text-indent:0em;margin-top:2em;">A long-term observational research study is collecting information about the diagnosis and treatment of cancer during pregnancy. For additional information about the pregnancy and cancer registry or to become a participant, contact Cooper Health (877-635-4499).</p></div>
<div class="block brc drugH1Div" id="F5957179"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if bendamustine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during treatment or for 1 week after the last bendamustine dose.</p></div>
<div class="block mop drugH1Div" id="F5957481"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">CBC with differential and platelets (frequently; in clinical trials, blood counts were monitored weekly initially); serum creatinine; LFTs (ALT, AST, and total bilirubin; prior to and during treatment); monitor potassium and uric acid levels in patients at risk for tumor lysis syndrome. Evaluate pregnancy status prior to use in patients who can become pregnant. Monitor for signs/symptoms of infusion reactions, anaphylaxis, infection (including reactivations), dermatologic toxicity, progressive multifocal leukoencephalopathy, and tumor lysis syndrome. Monitor IV site during and after infusion. Monitor for development of secondary malignancies, including dermatologic evaluations, during and after treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F5957479"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Bendamustine is an alkylating agent (nitrogen mustard derivative) with a benzimidazole ring (purine analog) which demonstrates only partial cross-resistance (<i>in vitro</i>) with other alkylating agents. It leads to cell death via single and double strand DNA cross-linking. Bendamustine is active against quiescent and dividing cells. The primary cytotoxic activity is due to bendamustine (as compared to metabolites). </p></div>
<div class="block phk drugH1Div" id="F5957371"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>ss</sub>: ~20 to 25 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 94% to 96%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic (extensive), via CYP1A2 to active (minor) metabolites gamma-hydroxy bendamustine (M3) and N-desmethyl-bendamustine (M4); also via hydrolysis to low cytotoxic metabolites, monohydroxy bendamustine (HP1) and dihydroxy bendamustine (HP2)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Bendamustine: ~40 minutes; M3: ~3 hours; M4: ~30 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Typically at end of infusion</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (~25%); urine (~50%; ~3% as active parent drug).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: ~700 mL/minute.</p>
<p style="text-indent:-2em;margin-left:2em;">Pharmacokinetic note: In a pharmacokinetic study, a 10-minute infusion of Bendeka (120 mg/m<sup>2</sup>) resulted in higher maximum plasma concentrations and equivalent systemic exposure as the same dose of Treanda infused over 60 minutes.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6875349"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Adesial | Bemux | Bendam | Bendamustina glenmark | Bendamustina gp pharm | Bendavar | Bendeka | Bendel | Bentaman | Benzimir | Endexin | Eriotib | Esevaril | Linfomustin | Mexed | Mubetin | Nalona | Queramus | Ribomustin</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Bendamustin accord | Bendamustin actavis | Bendamustin hikma | Bendamustin intas | Bendamustin kabi | Levact</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Ribomustin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Bendamustine accord | Levact</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Bendamustine accord | Bendamustine actavis | Bendamustine mylan | Bendamustine sandoz | Levact | Lynetoril | Ribomustin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Ribomustin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Bendamustin accord | Bendamustin sandoz | Ribomustin</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Bendamustina | Bendavar | Bendeka | Ribomustin</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Le wei xin | Treanda</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Bendal | Bendamustina | Besumid | Demustin | Genstina | Leukustim | Purpulz | Ramiza | Ribomustin | Xebina</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Bendamustin medac | Bendamustine accord | Bendamustine glenmark | Bendamustine kabi | Bendamustine pharmagen | Ledufan | Levact</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Benda nc | Bendamustin accord | Bendamustin axios | Bendamustin baxter | Bendamustin beta | Bendamustin cell pharm | Bendamustin chemi | Bendamustin hexal | Bendamustin hikma | Bendamustin kabi | Bendamustin medac | Bendamustin mylan | Bendamustin omnicare | Bendamustin onkovis | Bendamustin ribosepharm | Levact | Ribomustin</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Bendam | Ramiza</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Bendamustine accord | Bendamustine medac | Bendamustine sandoz | Ribomustin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Bendamustine hydrochloride accord | Ribomustin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Bendamustina accord | Bendamustina baxter | Bendamustina dr reddys | Bendamustina dr. reddy's | Bendamustina glenmark | Bendamustina intas | Bendamustina kabi | Bendamustina mylan | Bendamustina tillomed | Levact</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Bendit | Xyotin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Bendamustine accord | Bendamustine Avansor | Bendamustine intas | Bendamustine medac | Bendamyl | Levact</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Bendamustine accord | Bendamustine fresenius kabi | Bendamustine hikma | Bendamustine medac | Bendamustine mylan | Bendamustine reddy | Levact</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Bendamustine | Bendamustine hydrochloride accord | Levact</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Bendamustine accord | Bendamustine/accord | Bendamustine/actavis | Bendamustine/sandoz | Bentalya</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Treanda</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Benmak</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Bendamustin aramis | Bendamustin teva | Bendamustine accord | Bendamustine onkogen | Tabinaz</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Ribomustin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Bendamustine | Levact</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Bendit | Benzz | Bimode | Leuben | Mustin | Neomustin | Nexben | Purplz | Rolanda | Zumustin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Bendamustina accord | Bendamustina dr. reddy's | Bendamustina eg | Bendamustina Hikma | Bendamustina kabi | Bendamustina medac | Levact | Stinred</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Ribomustin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Bendamustine hydrochloride towa | Treakisym</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Bendalid | Symbenda</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Ribomustin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Bendavival | Ribomustin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Bendamustine accord | Bendamustine kabi | Bendamustine medac | Bendamustine sandoz</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Bendamustine accord | Bendamustine kabi | Bendamustine medac | Levact</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Ribomustin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Glindeka | Ribobustan | Ribomustin</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Levact | Ribomustin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Bendamustine | Bendamustine accord | Bendamustine Baxter | Bendamustine HCL Mylan | Bendamustine hcl teva | Levact</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Bendamustina kabi | Bendamustine accord | Bendamustine fresenius kabi | Levact | Ribomustin</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Bendamustine | Ribomustin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Bendam | Ribomustin</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Bendamustine | Ribomustin</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Bendamustine hydochloride</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Bendamustine accord | Bendamustine actavis | Bendamustine glenmark | Bendamustine intas | Bendamustine sandoz | Bendamustine stada | Bendamustine Zentiva | Levact | Ribomustin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Belrapzo | Bendamustine HCL | Bendeka | Treanda | Vivimusta</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Bendamustina accord | Bendamustina G.E.S. | Bendamustina Hikma | Levact</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Bemux | Bendam | Bendamustina Farmaco Uruguayo | Bendamustina gebina | Bendamustina varifarma | Esevaril | Ramiza | Ribomustin</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Ribomustin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Bendamustina accord | Bendamustina zentiva</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Kovada | Ribomustin | Rozustin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Ribomustin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Bendamustin actavis | Bendamustine accord | Bendamustine fresenius kabi | Bendamustine medac | Ribovact</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Bemunat | Symbenda</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Bendamustin accord | Bendamustin sandoz | Benmak | Levact</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Bendamustin medac | Bendamustine accord | Bendamustine actavis | Bendamustine glenmark | Bendamustine intas | Bendamustine kabi | Bendamustine mylan | Bendamustine pharmagen | Bendamustine sandoz | Ledufan | Levact | Lynetoril</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Ribomustin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Bemux | Levact</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Beastin | Bendamus | Bendustine | Levact</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Innomustine | Orimustine</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Bendamustine accord | Bendamusvista | Bentero | Ribomustin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Bendamustina Farmaco Uruguayo | Benzimir | Ramiza | Ribomustin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Bimode | Ribomustin | Spalbend</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12170428">
<a name="12170428"></a>Aivado M, Schulte K, Henze L, et al, “Bendamustine in the Treatment of Chronic Lymphocytic Leukemia: Results and Future Perspectives,” <i>Semin Oncol</i>, 2002, 29(4 Suppl 13):19-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/12170428/pubmed" id="12170428" target="_blank">12170428</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Belrapzo.1">
<a name="Belrapzo.1"></a>Belrapzo (bendamustine hydrochloride) [prescribing information]. Woodcliff Lake, NJ: Eagle Pharmaceuticals Inc; November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bendeka.1">
<a name="Bendeka.1"></a>Bendeka (bendamustine hydrochloride) [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals USA Inc; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin</i>
<i>Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20223726">
<a name="20223726"></a>Cheson BD, Wendtner CM, Pieper A, et al, “Optimal Use of Bendamustine in Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphomas, and Multiple Myeloma: Treatment Recommendations From an International Consensus Panel,” <i>Clin Lymphoma Myeloma Leuk</i>, 2010, 10(1):21-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/20223726/pubmed" id="20223726" target="_blank">20223726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23109692">
<a name="23109692"></a>Damaj G, Gressin R, Bouabdallah K, et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. <i>J Clin Oncol</i>. 2013. 31(1):104-10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/23109692/pubmed" id="23109692" target="_blank">23109692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25829094">
<a name="25829094"></a>Darwish M, Bond M, Hellriegel E, Robertson P Jr, Chovan JP. Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites. <i>Cancer Chemother Pharmacol</i>. 2015;75(6):1143-1154. doi:10.1007/s00280-015-2727-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/25829094/pubmed" id="25829094" target="_blank">25829094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dubbelman.1">
<a name="Dubbelman.1"></a>Dubbelman AC, Rosing H, Darwish M, et al, “An Open-Label Phase I Pharmacokinetic Study of [<sup>14</sup>c] Bendamustine in Patients with Relapsed or Refractory Malignancy,” <i>Blood</i>, 2011, 118(21):2746 [abstract 2746 from 2011 ASH Annual Meeting]</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21465637">
<a name="21465637"></a>Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/21465637/pubmed" id="21465637" target="_blank">21465637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23512831">
<a name="23512831"></a>Dupuis LL, Boodhan S, Holdsworth M, et al; Pediatric Oncology Group of Ontario. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/23512831/pubmed" id="23512831" target="_blank">23512831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29385883">
<a name="29385883"></a>Ettleson M, Bongers KS, Vitale K, Perissinotti AJ, Phillips T, Marini BL. Successful use of cytarabine and bendamustine in a patient with mantle cell lymphoma and acute renal failure using intermittent hemodialysis: a case report. <i>J Oncol Pharm Pract</i>. 2019;25(3):731-734. doi:10.1177/1078155217754244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/29385883/pubmed" id="29385883" target="_blank">29385883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21844497">
<a name="21844497"></a>Fischer K, Cramer P, Busch R, et al, “Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group,” <i>J Clin Oncol</i>, 2011, 29(26):3559-66.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/21844497/pubmed" id="21844497" target="_blank">21844497</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22869884">
<a name="22869884"></a>Fischer K, Cramer P, Busch R, et al, “Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group,” <i>J Clin Oncol</i>, 2012, 30(26):3209-16.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/22869884/pubmed" id="22869884" target="_blank">22869884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30811293">
<a name="30811293"></a>Flinn IW, van der Jagt R, Kahl B, et al. First-line treatment of patients with indolent non-hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. <i>J Clin Oncol</i>. 2019;37(12):984-991. doi:10.1200/JCO.18.00605<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/30811293/pubmed" id="30811293" target="_blank">30811293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24591201">
<a name="24591201"></a>Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. <i>Blood</i>. 2014;123(19):2944-2952. doi:10.1182/blood-2013-11-531327<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/24591201/pubmed" id="24591201" target="_blank">24591201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21810687">
<a name="21810687"></a>Fowler N, Kahl BS, Lee P, et al, “Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study,” <i>J Clin Oncol</i>, 2011, 29(25):3389-95.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/21810687/pubmed" id="21810687" target="_blank">21810687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18182663">
<a name="18182663"></a>Friedberg JW, Cohen P, Chen L, et al, “Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study,” <i>J Clin Oncol</i>, 2008, 26(2):204-10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/18182663/pubmed" id="18182663" target="_blank">18182663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21239695">
<a name="21239695"></a>Friedberg JW, Vose JM, Kelly JL, et al, “The Combination of Bendamustine, Bortezomib, and Rituximab for Patients With Relapsed/Refractory Indolent and Mantle Cell Non-Hodgkin Lymphoma,” <i>Blood</i>, 2011, 117(10):2807-12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/21239695/pubmed" id="21239695" target="_blank">21239695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26085055">
<a name="26085055"></a>Gentile M, Vigna E, Recchia AG, et al. Bendamustine in multiple myeloma. <i>Eur J Haematol</i>. 2015;95(5):377-388. doi:10.1111/ejh.12609<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/26085055/pubmed" id="26085055" target="_blank">26085055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28664772">
<a name="28664772"></a>Gordon MJ, Lewis LD, Brown JR, Danilov AV. Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose? <i>Expert Rev Hematol</i>. 2017;10(8):707-718. doi:10.1080/17474086.2017.1350166<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/28664772/pubmed" id="28664772" target="_blank">28664772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32658626">
<a name="32658626"></a>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/32658626/pubmed" id="32658626" target="_blank">32658626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21371003">
<a name="21371003"></a>Iannitto E, Morabito F, Mancuso S, et al, “Bendamustine With or Without Rituximab in the Treatment of Relapsed Chronic Lymphocytic Leukaemia: An Italian Retrospective Study,” <i>Br J Haematol</i>, 2011, 153(3):351-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/21371003/pubmed" id="21371003" target="_blank">21371003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19890959">
<a name="19890959"></a>Kahl BS, Bartlett NL, Leonard JP, et al, “Bendamustine Is Effective Therapy in Patients With Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma: Results From a Multicenter Study,” <i>Cancer</i>, 2010, 116(1):106-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/19890959/pubmed" id="19890959" target="_blank">19890959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22861163">
<a name="22861163"></a>Knauf WU, Lissitchkov T, Aldaoud A, et al, “Bendamustine Compared With Chlorambucil In Previously Untreated Patients With Chronic Lymphocytic Leukaemia: Updated Results of a Randomized Phase III Trial,” <i>Br J Haematol</i>, 2012, 159(1):67-77.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/22861163/pubmed" id="22861163" target="_blank">22861163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19652068">
<a name="19652068"></a>Knauf WU, Lissichkov T, Aldaoud A, et al, “Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic Leukemia (B-CLL),” <i>J Clin Oncol</i>, 2009, 27(26):4378-84.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/19652068/pubmed" id="19652068" target="_blank">19652068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16154860">
<a name="16154860"></a>Knop S, Straka C, Haen M, et al, “The Efficacy and Toxicity of Bendamustine in Recurrent Multiple Myeloma After High-Dose Chemotherapy,” <i>Haematologica</i>, 2005, 90(9):1287-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/16154860/pubmed" id="16154860" target="_blank">16154860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30942181">
<a name="30942181"></a>Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <i>Lancet Oncol</i>. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/30942181/pubmed" id="30942181" target="_blank">30942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22451423">
<a name="22451423"></a>Lentzsch S, O'Sullivan A, Kennedy RC, et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. <i>Blood</i>. 2012;119(20):4608-4613.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/22451423/pubmed" id="22451423" target="_blank">22451423</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24227817">
<a name="24227817"></a>Ludwig H, Kasparu H, Leitgeb C, et al, Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. <i>Blood</i>. 2014;123(7):985-991.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/24227817/pubmed" id="24227817" target="_blank">24227817</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20159666">
<a name="20159666"></a>Michael M, Bruns I, Bölke E, et al, “Bendamustine in Patients With Relapsed or Refractory Multiple Myeloma,” <i>Eur J Med Res</i>, 2010, 15(1):13-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/20159666/pubmed" id="20159666" target="_blank">20159666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23248254">
<a name="23248254"></a>Moskowitz AJ, Hamlin PA Jr, Perales MA, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. <i>J Clin Oncol</i>. 2013;31(4):456-460.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/23248254/pubmed" id="23248254" target="_blank">23248254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23987821">
<a name="23987821"></a>Nordstrom BL, Knopf KB, Teltsch DY, Engle R, Beygi H, Sterchele JA. The safety of bendamustine in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma and concomitant renal impairment: a retrospective electronic medical record database analysis. <i>Leuk Lymphoma</i>. 2014;55(6):1266-1273. doi:10.3109/10428194.2013.836600<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/23987821/pubmed" id="23987821" target="_blank">23987821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20140617">
<a name="20140617"></a>Owen JS, Melhem M, Passarell JA, et al. Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma. <i>Cancer Chemother Pharmacol</i>. 2010;66(6):1039-1049.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/20140617/pubmed" id="20140617" target="_blank">20140617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23813932">
<a name="23813932"></a>Peccatori FA, Azim HA Jr, Orecchia R, et al; ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24(suppl 6):vi160-170. doi: 10.1093/annonc/mdt199.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/23813932/pubmed" id="23813932" target="_blank">23813932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22997449">
<a name="22997449"></a>Pérez Fidalgo JA, García Fabregat L, Cervantes A, et al, “Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines,” <i>Ann Oncol</i>, 2012, 23(Suppl 7):167-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/22997449/pubmed" id="22997449" target="_blank">22997449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Polovich.1">
<a name="Polovich.1"></a>Polovich M, Whitford JN and Olsen M, <i>Chemotherapy and Biotherapy Guidelines and Recommendations for Practice</i>, 3rd ed, Pittsburgh, PA: Oncology Nursing Society, 2009.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12170429">
<a name="12170429"></a>Ponisch W and Niederwieser D, “Bendamustine in the Treatment of Multiple Myeloma: Results and Future Perspectives,” <i>Semin Oncol</i>, 2002, 29(4 Suppl 13):23-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/12170429/pubmed" id="12170429" target="_blank">12170429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22526157">
<a name="22526157"></a>Ponisch W, Andrea M, Wagner I, et al. Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. <i>J Cancer Res Clin Oncol.</i> 2012;138(8):1405-1412. doi:10.1007/s00432-012-1212-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/22526157/pubmed" id="22526157" target="_blank">22526157</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24046251">
<a name="24046251"></a>Ponisch W, Moll B, Bourgeois M, et al. Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure. <i>J Cancer Res Clin Oncol.</i> 2013;139(11):1937-1946. doi:10.1007/s00432-013-1513-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/24046251/pubmed" id="24046251" target="_blank">24046251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29168251">
<a name="29168251"></a>Ribes D, Hachem HEL, Oberic L, et al. Bendamustine plus rituximab for indolent B-cell lymphoma of renal significance.<i> Am J Hematol</i>. 2018;93(3):356-362. doi:10.1002/ajh.24984<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/29168251/pubmed" id="29168251" target="_blank">29168251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18626004">
<a name="18626004"></a>Robinson KS, Williams ME, van der Jagt RH, et al, “Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma,” <i>J Clin Oncol</i>, 2008, 26(27):4473-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/18626004/pubmed" id="18626004" target="_blank">18626004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27664248">
<a name="27664248"></a>Roila F, Molassiotis A, Herrstedt J, et al; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133. doi: 10.1093/annonc/mdw270.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/27664248/pubmed" id="27664248" target="_blank">27664248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15908650">
<a name="15908650"></a>Rummel MJ, Al-Batran SE, Kim SZ, et al, “Bendamustine Plus Rituximab is Effective and has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma,” <i>J Clin Oncol</i>, 2005, 23(15):3383-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/15908650/pubmed" id="15908650" target="_blank">15908650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23433739">
<a name="23433739"></a>Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. <i>Lancet</i>. 2013. 381(9873):1203-10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/23433739/pubmed" id="23433739" target="_blank">23433739</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sandhu.1">
<a name="Sandhu.1"></a>Sandhu G, Adattini J, Armstrong Gordon E, O’Neill N; ADDIKD Guideline Working Group. International consensus guideline for anticancer drug dosing in kidney dysfunction 2022. https://www.eviq.org.au/clinical-resources/addikd-guideline/4174-anticancer-drug-dosing-in-kidney-dysfunction. Published 2022. Accessed August 08, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21255716">
<a name="21255716"></a>Schulmeister L, "Extravasation Management: Clinical Update," <i>Semin Oncol Nurs</i>, 2011, 27(1):82-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/21255716/pubmed" id="21255716" target="_blank">21255716</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27345636">
<a name="27345636"></a>Sehn LH, Chua N, Mayer J, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicenter, phase 3 trial. <i>Lancet Oncol</i>. 2016;17(8):1081-1093.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/27345636/pubmed" id="27345636" target="_blank">27345636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31693429">
<a name="31693429"></a>Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. <i>J Clin Oncol</i>. 2020;38(2):155-165. doi:10.1200/JCO.19.00172<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/31693429/pubmed" id="31693429" target="_blank">31693429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23645657">
<a name="23645657"></a>Shoji J, Lew SQ. The use of rituximab and bendamustine in treating chronic lymphocytic leukaemia (CLL) in end-stage renal disease (ESRD). <i>BMJ Case Rep</i>. Published online May 2, 2013. doi:10.1136/bcr-2013-009637<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/23645657/pubmed" id="23645657" target="_blank">23645657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Smetzer.1">
<a name="Smetzer.1"></a>Smetzer J, Cohen M, eds. Update on bendamustine and CSTDs. <i>ISMP Medication Safety Alert! Acute Care Edition</i>. 2015;20(5):2-3.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21306291">
<a name="21306291"></a>Tapan U, May SK, Fiore J, et al, “Reactivation of Hepatitis B Virus Following Bendamustine-Containing Chemotherapy in a Patient With Multiple Myeloma,” <i>Leuk Lymphoma</i>, 2011, 52(5):916-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/21306291/pubmed" id="21306291" target="_blank">21306291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16957931">
<a name="16957931"></a>Teichert J, Baumann F, Chao Q, et al, “Characterization of Two Phase I Metabolites of Bendamustine in Human Liver Microsomes and in Cancer Patients Treated With Bendamustine Hydrochloride,” <i>Cancer Chemother Pharmacol</i>, 2007, 59(6):759-70.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/16957931/pubmed" id="16957931" target="_blank">16957931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15845750">
<a name="15845750"></a>Teichert J, Sohr R, Baumann F, et al, “Synthesis and Characterization of Some New Phase II Metabolites of the Alkylator Bendamustine and Their Identification in Human Bile, Urine, and Plasma From Patients With Cholangiocarcinoma,” <i>Drug Metab Dispos</i>, 2005, 33(7):984-92.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/15845750/pubmed" id="15845750" target="_blank">15845750</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Teva.1">
<a name="Teva.1"></a>Teva US Specialty Medicines. Treanda medical information [written communication]. North Wales, PA: Teva Pharmaceuticals; February 11, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Treanda.1">
<a name="Treanda.1"></a>Treanda (bendamustine) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA Inc; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Treanda.2">
<a name="Treanda.2"></a>Treanda (bendamustine) [prescribing information]. Parsippan, NJ: Teva Pharmaceuticals USA Inc; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21454214">
<a name="21454214"></a>Treon SP, Hanzis C, Tripsas C, et al, “Bendamustine Therapy in Patients With Relapsed or Refractory Waldenström's Macroglobulinemia,” <i>Clin Lymphoma Myeloma Leuk</i>, 2011, 11(1):133-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/21454214/pubmed" id="21454214" target="_blank">21454214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin</i>
<i>Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/</a>. Updated September 2016. Accessed October 28, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vivimusta.1">
<a name="Vivimusta.1"></a>Vivimusta (bendamustine hydrochloride) [prescribing information]. Princeton, NJ: Slayback Pharma LLC; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33938097">
<a name="33938097"></a>Yasuda H, Yasuda M, Komatsu N. Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: a comprehensive review. <i>Cancer Sci.</i> 2021;112(7):2607-2624. doi:10.1111/cas.14933<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/33938097/pubmed" id="33938097" target="_blank">33938097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T. Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bendamustine-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9323 Version 340.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
